Compare Cassava Sciences Inc (FLNA) vs L3Harris Technologies Inc (LHX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Cassava Sciences Inc vs L3Harris Technologies Inc — how do they compare? Cassava Sciences Inc trades at $1.06 (market cap $53.14M), while L3Harris Technologies Inc trades at $284.34 (market cap $53.43B). The key difference: L3Harris Technologies Inc is far larger — about 1005.5× Cassava Sciences Inc's market cap, and L3Harris Technologies Inc pays a 1.74% dividend while Cassava Sciences Inc pays none. Which is the better fit depends on your goals.
| FLNA | LHX | |
|---|---|---|
Market Cap | $53.14M | $53.43B |
Sector | Health | Industrials |
52-Week High | $4.64 | $378.48 |
52-Week Low | $1.09 | $263.09 |
Enterprise Value | -$33.43M | $64.20B |
Dividend Yield | — | 1.74% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
FLNA trades at $1.06, down 2.75% today, with a bearish technical signal from moving averages but neutral oscillators. The stock shows a low P/B of 0.78, yet profitability metrics are negative, including a -79.59% ROE and -$90.97M net income for 2025. Recent Q1 2026 earnings beat expectations, and analyst consensus is 66.7% buy. News highlights Q1 financial results and a scientific presentation on TSC-related epilepsy therapies.
Outlook remains speculative due to persistent losses and negative cash flows, offset by strong analyst support and recent earnings beats. Key risks include funding needs for drug development and competitive pressures, while potential upside hinges on clinical progress in TSC-related epilepsy treatments.
LHX trades at $283.29, down 2.32% on the day, amid a bearish technical signal but strong fundamentals. The company has beaten EPS estimates for three consecutive quarters, with revenue growing to $21.87B in 2025 and net income reaching $1.61B. Recent contract wins from the U.S. Space Force and Army highlight ongoing defense demand, while analyst consensus remains strongly bullish with a $367.50 price target.
The outlook for LHX is positive given its record backlog and government contracts, though risks include execution on growth initiatives and defense budget volatility. With a P/E of 31.14, the stock trades at a premium to historical averages, but institutional support and dividend payments provide stability. Near-term performance hinges on Q2 2026 earnings due next.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Cassava Sciences Inc
Cassava Sciences Inc is a clinical-stage biotechnology company engaged in developing a scientific approach for the treatment and detection of Alzheimer's disease. Its therapeutic product candidate is called simufilam, and it is a novel treatment for Alzheimer's disease
Read more on FLNA →About L3Harris Technologies Inc
L3Harris Technologies was created in 2019 from the merger of L3 Technologies and Harris, two defense contractors that provide products for the command, control, communications, computers, intelligence, surveillance, and reconnaissance (C4ISR) market. The firm also has smaller operations serving the civil government, particularly the Federal Aviation Administration's communication infrastructure, and produces various avionics for defense and commercial aviation.
Read more on LHX →
